Multi-valent hepatitis B virus antigen binding molecules and uses thereof
AssigneeIGM Biosciences, Inc.
InventorsStephen F. Carroll, Ramesh Baliga, Dean Ng, Bruce Keyt
Life of this patent
Estimating the term…
Abstract
This disclosure provides a multimeric hepatitis B virus (HBV) protein binding molecule, e.g., a dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HBV antigen binding domain. The disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.
Claims19
A multimeric binding molecule comprising at least two IgA bivalent binding units, or variants or fragments thereof and a J-chain or fragment or variant thereof;
- wherein the J-chain or fragment or variant thereof is modified to comprise a heterologous polypeptide directly or indirectly fused to the J-chain or fragment or variant thereof,
- wherein each IgA binding unit comprises at least two IgA antibody heavy chain constant regions or fragments thereof, each associated with an antigen binding domain;
- wherein the antigen binding domains specifically bind to a hepatitis B virus (HBV) antigen expressed on the surface of infectious viral particles, on the surface of HBV infected cells, or a combination thereof, and
- wherein the binding molecule is more potent than a reference IgG antibody comprising the antigen binding domain that specifically binds to the HBV antigen.
Dependencies are inferred from the claim text.